Swedish vaccine innovation company ZICCUM AB has been accepted as a member of NIIMBL, the US National Institute for Innovation in Manufacturing Biopharmaceuticals. NIIMBL drives innovation and uptake of new technologies within biopharmaceutical manufacturing in the US. Ziccum’s LaminarPace technology air-dries vaccines and biologics at ambient temperatures, producing stable, dry-powder vaccines requiring no Cold Chain for storage or transportation.
NIIMBL is a public-private partnership spanning government, the biopharma industry, academia, trade organisations and more. It is co-funded by the the US National Institute of Standards and Technology (NIST), the U.S. Department of Commerce and members. NIIMBL’s mission is accelerating the development and uptake of next-generation biopharmaceutical manufacturing technologies within the US.
Ziccum CEO Göran Conradson: “It is an honour to be accepted as a member of NIIMBL, especially as a foreign bio-research company. Right now, innovation in biopharmaceutical manufacturing has never been more urgent. It is a global priority for all of us. We look forward to being active, collaborative and responsible members.”
- Read more about NIIMBL here.
- Read more about LaminarPace here.
- Ziccum’s plans for regional Fill and Finish plants here.
- Ziccum technology preparing for pandemics and reducing vaccine waste here.